Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01915823 |
|
Recruitment Status :
Completed
First Posted : August 5, 2013
Results First Posted : June 29, 2015
Last Update Posted : June 29, 2015
|
Sponsor:
Meda Pharmaceuticals
Information provided by (Responsible Party):
Meda Pharmaceuticals
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Seasonal Allergic Rhinitis | Drug: azelastine hydrochloride and fluticasone propionate Drug: Dymista vehicle | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 348 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages >4 Years to <12 Years With Seasonal Allergic Rhinitis |
| Study Start Date : | July 2013 |
| Actual Primary Completion Date : | February 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Hay Fever
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Dymista
(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily |
Drug: azelastine hydrochloride and fluticasone propionate
Other Name: Dymista |
|
Placebo Comparator: Dymista vehicle
Dose: vehicle only Regimen: 1 spray per nostril twice daily
|
Drug: Dymista vehicle
Other Name: placebo |
Primary Outcome Measures :
- Primary Efficacy [ Time Frame: 15 days of treatment ]change from baseline in AM+PM rTNSS (reflective total nasal symptoms score): ITT( intent to treat population)change from baseline in 12-hour reflective total nasal symptom score (rTNSS) consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary for the entire 14 day study period.The measurement scale is 0 to 24 so that the higher the number the worse the symptom.A reduction in symptom severity score is indicated by a negative value.A greater negative value suggests improvement.
Secondary Outcome Measures :
- Safety [ Time Frame: entire length of study (day 1 to day 22) ]
- Subject-reported adverse experiences (incidence, type, and severity of adverse events)
- Nasal Examinations
- Vital signs assessments
Other Outcome Measures:
- Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) [ Time Frame: day 1 to day 15 of treatment ]Change from baseline to Visit 4 in the ITT ( intent to treat) Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) in subjects equal to or greater than 6 years old and less than12 years old compared to placebo.Scored on a 0 to 7 scale with 0 being not troubled at all and 7 being extremely troublesome. The higher the difference the better the result.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years to 11 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and female subjects ages >4 years to <12 years of age, inclusive at the screening visit
- The parent/caregiver must provide written informed consent and the child must provide pediatric assent, if possible
- Willing and able to comply with the study requirements
- Have a history of seasonal allergic rhinitis (SAR) to pollen in the prevailing allergy season.
- The presence of immunoglobulin E (IgE)-mediated hypersensitivity to prevailing pollen, confirmed by a positive response to skin prick test. A histamine skin test must also be positive. A positive response for both the pollen skin test and the histamine skin test is defined as a wheal diameter of at least 4 mm larger than the negative saline control
- General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
- On the first day of the placebo lead-in period (Visit 1) subjects must have a 12-hour reflective total nasal symptoms score (rTNSS )of ≥6 and a reflective congestion score of ≥2 to qualify for entry.
At Visit 2:
- Have taken at least 6 doses of the placebo lead-in medication during the placebo lead-in period
-
At Visit 2, to be eligible for entry into the double-blind treatment period, subjects must have the total of the seven lead-in symptom assessments during the past 3 days of the lead-in period including the Day of Randomization (Visit 2, Day 1):
- a 12-hour reflective TNSS ≥ 42
- a 12-hour reflective congestion score of ≥14
Exclusion Criteria:
- On nasal examination, the presence of any superficial or moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation (Grade 1B - 4) at either the screening visit or randomization visit
- Nasal disease(s) likely to affect deposition of intranasal medication, such as acute or chronic sinusitis, rhinitis medicamentosa, clinically significant polyposis, or clinically significant nasal structural abnormalities.
- Nasal surgery or sinus surgery within the previous year.
- The use of any investigational drug within 30 days prior to signing the informed consent/pediatric assent at Visit 1. No investigational products are permitted for use during the conduct of this study
- Presence of any hypersensitivity to azelastine hydrochloride and/or fluticasone propionate or drugs similar to azelastine hydrochloride and/or fluticasone propionate
- Respiratory tract infections within 14 days prior to Visit1
- Significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
- Chronic obstructive sleep apnea syndrome (clinical diagnosis)
- Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug that might significantly affect the subject's ability to complete this trial
- Clinically relevant abnormal physical findings which, in the opinion of the investigator or sponsor's medical monitor, would interfere with the objectives of the study or that may preclude compliance with the study procedures
- Family members of the research center or private practice personnel who are directly involved in this study are excluded
- Members of the same household cannot be enrolled at the same time
- Subjects who have used medications or therapies that could interfere with safety and efficacy evaluations and have not had the proper washouts from these medications or therapies
- Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism
- Positive pregnancy test in female subjects ≥ 9 years of age
- Females who are pregnant or nursing
- Females of childbearing potential who are not abstinent and not practicing a medically acceptable method of contraception
- Subjects who fail to complete the symptom diary during the lead-in period, defined as missing data for >50% of entries
- Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimens following a brief period of missed injections do not preclude participation). Dose reduction when a new bottle is used does not preclude participation.
- Planned travel outside of the pollen area during the study period
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01915823
Locations
Show 31 study locations
Sponsors and Collaborators
Meda Pharmaceuticals
| Responsible Party: | Meda Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01915823 |
| Other Study ID Numbers: |
MP 4008 |
| First Posted: | August 5, 2013 Key Record Dates |
| Results First Posted: | June 29, 2015 |
| Last Update Posted: | June 29, 2015 |
| Last Verified: | June 2015 |
Additional relevant MeSH terms:
|
Rhinitis Rhinitis, Allergic Rhinitis, Allergic, Seasonal Respiratory Tract Infections Infections Nose Diseases Respiratory Tract Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Fluticasone Xhance Azelastine |
Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Dermatologic Agents Anti-Allergic Agents Lipoxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Histamine H1 Antagonists, Non-Sedating Histamine H1 Antagonists Histamine Antagonists |